SCHEMBL1865020

SCHEMBL1865020

Cc1oc(-c2ccccc2)nc1CC1COC(C)(C(=O)NOCc2ccccc2)OC1

nearest known ligand 0.63

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 18/20 0.63
PPARG P37231 13/20 0.63
KDM4E B2RXH2 1/20 0.45
FFAR1 O14842 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1867010 0.95 PPARA (0.62) PPARAPPARG
SCHEMBL1864512 0.95 PPARA (0.57) PPARAPPARG
SCHEMBL1874479 0.93 PPARA (0.60) PPARAPPARG
SCHEMBL1864785 0.92 PPARA (0.56) PPARAPPARG
SCHEMBL1870161 0.91 PPARA (0.62) PPARAPPARG
SCHEMBL1875241 0.86 PPARA (0.57) PPARAPPARG
SCHEMBL1864240 0.85 PPARA (0.68) PPARAPPARGKDM4E
SCHEMBL12802663 0.83 PPARA (0.65) PPARAPPARGKDM4E
SCHEMBL1867362 0.83 PPARA (0.80) PPARAPPARGKDM4E
SCHEMBL1893065 0.82 PPARG (0.62) PPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2483266-B1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LTD (IN) 2015-02-25 EP claimed
EP-2567957-A1 Compounds for the treatment of dyslipidemia and related diseases CADILA HEALTHCARE LIMITED (IN) 2013-03-13 EP claimed
US-20120252796-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LIMITED (IN) 2012-10-04 US claimed
EP-2483266-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES Cadila Healthcare Limited (IN) 2012-08-08 EP claimed
WO-2011051961-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LIMITED (IN) 2011-05-05 WO claimed
EP-2483266-B1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LTD (IN) 2015-02-25 EP disclosed
EP-2567957-A1 Compounds for the treatment of dyslipidemia and related diseases CADILA HEALTHCARE LIMITED (IN) 2013-03-13 EP disclosed
US-20120252796-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LIMITED (IN) 2012-10-04 US disclosed
EP-2483266-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES Cadila Healthcare Limited (IN) 2012-08-08 EP disclosed
WO-2011051961-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LIMITED (IN) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252796-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES PCSK9, APOB, CPT1A PPARA 132/4885PPARG 122/4885KDM4E 3925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.